Exclusive Summary

• Magnesium Sulfate Injection is listed on the WHO Essential Medicines List and holds an irreplaceable first-line position in eclampsia/pre-eclampsia treatment, generating rigid annual demand from approximately 7–11 million affected pregnancies worldwide.
• With all patents long expired and the market fully open to generics, Chinese suppliers can offer highly competitive pricing backed by mature manufacturing processes and scale, making this product particularly attractive to buyers in budget-constrained emerging markets.
• Beyond obstetrics, the drug is guideline-recommended across multiple indications including hypomagnesemia, arrhythmia, and acute severe asthma, broadening the potential customer base across multiple hospital departments.
• Significant supply gaps and unmet clinical coverage exist in LMICs across Southeast Asia, Africa, the Middle East, and Latin America, where maternal mortality remains high and magnesium sulfate access is still insufficient, representing clear incremental market opportunity.
• Chinese pharmaceutical manufacturers with FDA/WHO-PQ/EU GMP certifications can meet diverse regulatory requirements across target markets, enabling rapid market entry through a Distribution partnership model.